The first in a series of Dotmatics Luma Multimodal R&D Solutions

Geneious has been seamlessly composed into Luma showcasing cross-therapeutic capabilities within a unified platform

BOSTON, Oct. 22, 2024 /PRNewswire/ — Dotmatics®, a leader in R&D scientific software connecting science, data, and decision-making, today announced the launch of Dotmatics Luma™ Multimodal R&D Solutions in support of the discovery and development of therapeutics across multiple modalities of biopharmaceutical science. The first solution is the Luma Antibody & Protein Engineering solution, a comprehensive end-to-end solution for streamlining the antibody discovery and development process, with an emphasis on monoclonal and multispecific antibodies.

The Luma Antibody & Protein Engineering Solution and other future multimodal solutions combine the Dotmatics Luma Scientific Intelligence Platform and key Dotmatics scientific tools, thoughtfully composed within Luma. Together, these solutions will offer researchers a multimodal approach to therapeutic discovery supporting CAR-T cell discovery, siRNA, antibody-drug conjugates (ADCs), CRISPR therapeutics, and vaccine discovery.

“Increasingly our customers are asking for tools that support multiple modalities of therapeutic discovery,” said Michael Swartz, Chief Strategy Officer at Dotmatics. “Scientists want to pick the best therapy or combination of therapies to address a particular target by researching and testing across different domains of science – not just one. Dotmatics gives them a scientific intelligence platform that is natively built to support this.”

These multimodal Luma solutions will leverage capabilities from Dotmatics’ best-in-class scientific software products including Geneious®, GraphPad® Prism, OMIQ®, Protein Metrics Byos®, and FCS Express®, composed to work together harmoniously within Luma, enhancing overall functionality without friction. This approach allows researchers to use familiar tools while eliminating data and process silos, creating a more cohesive and collaborative environment.

Introducing Geneious Luma

The first of these scientific products seamlessly composed within Luma and being introduced today is Geneious Luma. With Geneious Luma, researchers will have access to analyze and visualize DNA, RNA, and protein sequences from Geneious Prime, and the antibody discovery and screening capabilities of Geneious Biologics.

Geneious Luma, and the other future Dotmatics scientific products composed within Luma, will each come pre-configured to work seamlessly within Luma, while allowing IT and scientists to compose their own sequence of sophisticated low-code actions, eliminating the need for lengthy customization or complex integrations. As a result, researchers can benefit from the end-to-end solution immediately. In addition, these products will be available to license together with the Luma platform and will include out-of-the-box Luma applications to fill critical gaps in the end-to-end workflow, including:

Multimodal Registration: Versioned, entity-specific, and extensible registration models driven by linked ontologies allow for the highest levels of scientific depth and precision. Luma links these models to how scientists naturally work, so registration happens automatically and asynchronously, along with the tracking and storage of experimental and product-related information throughout the research and development process. When test results indicate a synthesized molecule does not match the design, Luma can modify the linked registered entity without losing lineage or context of the original.Unified Results: All relevant project data—such as molecule designs, characterization data, assay data, endpoint data, and registered materials—can be correlated and unified into normalized data structures and customizable dashboards to quickly make decisions about which antibodies are best to advance. This happens automatically as people work, eliminating the need for hours of data wrangling currently implicit in activities from registration to analysis.Customer Apps: Customers can safely extend Dotmatics Luma apps or create their own low-code apps to contextualize, flow, and correlate data from disparate sources in ways that suit their needs – with scientifically smart dashboards and visualizations to match. These apps follow industry standard SDLC processes and FAIR data principles to make getting data into and out of Luma in a governed way simple and straightforward. Data integration options include REST, GraphQL, and JDBC.Artificial Intelligence: Luma will include significant generative and predictive ML capabilities for dry lab and wet lab tasks that customers can define and extend. Assistive GenAI will help customers accelerate the introspection, summarization, and visualization of their data. Domain-specific AI will allow Luma to leverage protein prediction, flow cytometry autogating, and other scientifically-focused models within their workflows. Composite AI will allow the use of multiple models or data sets generated from independent models to be brought together for higher order model training, selection, and execution.

The Luma Antibody & Protein Engineering Solution

By composing Geneious Luma and other scientific products within Luma, Dotmatics can offer researchers with a new solution for addressing the complexities of antibody and protein engineering.

“The Luma Antibody & Protein Engineering solution addresses long-standing gaps in the antibody discovery workflow by providing an end-to-end process that seamlessly composes many of scientists’ favorite tools directly into Luma,” said Kalim Sailba, Chief Product Officer at Dotmatics. “Researchers can now streamline workflows from planning and in-silico design to wet lab production, validation, and data analysis, all within a unified AI-native platform.”

The following products, composed within Luma, will support the Luma Antibody & Protein Engineering solution:

Geneious Luma: Enables researchers to use the advanced bioinformatics, molecular biology, and antibody discovery capabilities of Geneious Prime® and Geneious Biologics® to annotate and filter sequences and to design constructs. Then, seamlessly working together with Luma, researchers can execute their cloning, expression, and purification tasks using Luma’s Adaptive Workflow capabilities.

Customers will also have access to BioGlyph®, following Dotmatics’ recent investment, enabling the design and generation of multispecific antibody formats and the execution of predictive machine learning models to score potential multispecific antibodies, allowing researchers to explore all combinations of multispecific formats and proceed with only those that are most promising.

Prism Luma: Leverage GraphPad Prism, the industry-leading data analysis software, for antibody assay development and screening. This product includes native normalization and pre-processing of results prior to analysis in Prism (mitigating the need to use Excel) and contextual linking between assay results, registered materials, and experimental context.Byos & Byosphere Luma: Use Protein Metrics Byos, a comprehensive software for streamlining protein characterization, to characterize protein structures and behaviors for higher fidelity, then feed these characterizations back into predictive machine learning models to drive the next round of synthesis. Also leverage Protein Metrics Byosphere enterprise platform to combine biotherapeutic mass spec data, analysis, and reporting and to curate, interrogate, and share information gained in the analytical lab from Byos.Luma Lab Connect: Automate data ingestion from lab instruments including flow cytometry, liquid chromatography, mass spectrometry and other data sources. Lab Connect auto-associates instrument results with the correct workflow steps, materials, and endpoint data, mitigating a common manual pain point of SDMS and LIMS systems today.Flow Luma: Use OMIQ, the modern flow cytometry solution, to evaluate the molecular properties of antibody candidates, the cells that produce them, and phenotype their therapeutic outcomes.

Expanding Beyond Biopharma

The future use of Dotmatics Luma extends beyond biopharma and drug discovery into broader scientific domains, like material science and chemistry, industrial biotech, and agritech. Every solution built on the Luma platform ensures a unified user experience and seamless work and data flows, helping organizations achieve scientific breakthroughs faster and with greater accuracy. By delivering a cohesive and scalable platform, Dotmatics aims to support researchers across multiple industries, fostering innovation and collaboration.

Forward Looking Statements  

This press release contains forward-looking statements that are intended to outline our general product strategy. It is intended for informational purposes only and speaks only as of the date the statements are first published. It is not a commitment to deliver any functionality and should not be relied upon for making purchase decisions. You should not put any contractual reliance on these statements. The development, release, and timing of any products or capabilities remains at the sole discretion of Dotmatics.

No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. Only those representations or warranties that are made in or pursuant to one or more definitive agreements involving the parties will have any legal effect.

About Dotmatics
Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and scientists’ favorite applications drive efficiency and accelerate innovation. More than 2 million scientists and 10,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. Dotmatics is a global team of more than 800 people dedicated to supporting its customers in over 180 countries. Dotmatics has made 14 acquisitions since 2017. The company’s principal office is in Boston, with 14 offices and R&D teams located around the world.

Dotmatics is backed by Insight Partners, a leading global venture capital and private equity firm investing in high-growth technology and software scaleup companies. Learn more about Dotmatics, its platform, and applications including GraphPad Prism, Geneious, SnapGene, Protein Metrics, and LabArchives at https://www.dotmatics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dotmatics-introduces-luma-antibody–protein-engineering-solution-for-end-to-end-antibody-discovery-302282480.html

SOURCE Dotmatics Inc

LONDON, Oct. 22, 2024 /PRNewswire/ — In response to increasingly disruptive attacks on UK healthcare systems, the Cheshire and Merseyside ICS (Integrated Care System) has chosen Cynerio’s Healthcare Cybersecurity Platform to deepen their defences. After thorough evaluation of multiple options, the UK’s largest ICS will be implementing Cynerio’s full platform at all 17 NHS Trusts.

Ransomware attacks have become a significant concern for healthcare organisations worldwide, with notable attacks impacting all corners of the NHS. The impact of these attacks on patients and facilities lead Cheshire and Merseyside to proactively invest in greater defences, eventually leading to the implementation of Cynerio’s platform which is designed to protect healthcare environments against threats to Internet of Things (IoT) and other connected devices. With the adoption of Cynerio, Cheshire and Merseyside aims to better protect patient data, minimise vulnerabilities, and reduce disruptions to care.

“Cynerio delivered exactly what we needed: comprehensive visibility into all networked medical devices across our ICS trusts. Deployment was efficient, and the vendor’s support was consistently responsive, helping us enhance our security posture and fortify our cybersecurity defences.” said Matt Connor, Chief Digital Information Officer at Liverpool Womens Hospital NHS Foundation Trust.

Cynerio is increasingly recognized as an industry leader in healthcare cybersecurity, including in the UK where 1 in every 4 hospitals are using Cynerio. The platform’s innovative technology is designed to continuously monitor, detect, and mitigate cybersecurity threats specific to medical and IoT devices within healthcare environments. Its real-time threat intelligence and automated response mechanisms provide a robust defence against emerging cyber risks.

Darrell Bailey, Head of Sales for Cynerio, expressed his enthusiasm for the collaboration, saying, “We are extremely proud to have been chosen by Cheshire and Merseyside to defend all the care facilities in the ICS. Adopting best of breed technologies like Cynerio to be deployed at scale will allow them to continue to be a leader and innovator in the NHS.”

Cheshire and Merseyside’s adoption of the Cynerio platform is a logical step forward in ensuring the integrity and resilience of healthcare operations. This proactive cybersecurity initiative reinforces the organisation’s mission to provide the highest quality of care while safeguarding patient data against evolving threats.

About Cynerio:
Cynerio is a cybersecurity and compliance solution customised for the NHS. We go beyond asset management by protecting IoT and connected medical devices from ransomware and other live attacks. Cynerio has one simple goals – Intelligent prioritisation and protection of your critical devices based on clinical context, exploit probability, impact to patient care and DSP compliance. For more information visit www.cynerio.com, and follow us on linkedin www.linkedin.com/company/cynerio 

Media Contact:
Name: Vicki Michaeli
Email: vicki@cynerio.com

Logo – https://mma.prnewswire.com/media/1876294/Cynerio_Logo_Logov1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/cheshire-and-merseyside-health-and-care-partnership-secure-patient-care-with-cynerio-302283021.html

NEW DELHI, Oct. 22, 2024 /PRNewswire/ — Appy Pie, a leader in no-code development, announces the launch of its AI App Generator GPT, now available on the GPT Store. This innovative tool enables users to create Android and iOS apps simply by describing their ideas through text prompts. Powered by GPT-4, it offers enhanced functionality through advanced natural language understanding. This release underscores Appy Pie’s ongoing mission to make app development more accessible for everyone.

The AI App Generator streamlines the app development process through its sophisticated natural language processing. By generating precise app drafts from user input, it significantly accelerates the initial development stages. Leveraging extensive datasets, the model produces outputs tailored to user specifications. It also interprets complex commands and provides suggestions aligned with specific app goals.

To start building an app, users can access the AI App Generator GPT in the “Explore GPTs” section of ChatGPT-4. By entering a brief text description of their app requirements, users receive a draft application tailored to their input. They can then refine this draft using customizable templates from the Appy Pie App Builder platform, adjusting layouts, features, fonts, and designs to suit their needs. The platform’s intuitive drag-and-drop interface makes app creation simple, even for those without coding experience.

Abhinav Girdhar, CEO of Appy Pie, highlighted the significance of this update: “Our mission is to provide tools that make app creation simple and fast. This launch marks a significant advancement for the app development industry. With the AI App Generator GPT, we empower anyone to transform their ideas into fully functional apps without technical challenges using Chat GPT. This development aligns with our goal of making technology accessible to all.”

For businesses seeking to simplify app development, the AI App Generator GPT from Appy Pie presents a valuable and practical solution. Appy Pie remains committed to driving innovation in the no-code development sector. This commitment equips businesses with essential tools for success.

About Appy Pie

Appy Pie is a leading global platform offering a suite of no-code, AI-powered tools, including an app builder, website builder, workflow automation platform, graphic design software, chatbot builder, help desk software, and live chat software, to help businesses and individuals design, build, and automate. With a user-friendly interface and a wide range of customizable templates, Appy Pie empowers users to create professional-grade applications without any coding expertise. From entrepreneurs to established enterprises, Appy Pie caters to diverse needs by providing innovative solutions for various industries.

For more information, please visit: https://www.appypie.com/ 

Media Contact
Abhinav Girdhar
sales@appypie.com
+1 888 322 7617

View original content to download multimedia:https://www.prnewswire.com/news-releases/appy-pie-launches-no-code-ai-app-generator-gpt-on-gpt-store-302282922.html

SOURCE Appy Pie